Previous close | 3.9300 |
Open | 3.9400 |
Bid | 3.8800 x 100 |
Ask | 3.9200 x 200 |
Day's range | 3.8901 - 4.1700 |
52-week range | 1.4200 - 11.9700 |
Volume | |
Avg. volume | 589,182 |
Market cap | 230.283M |
Beta (5Y monthly) | 1.52 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6400 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.25 |
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
LEXINGTON, Mass., April 18, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Thursday, April 25, 2024 in New York City.
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.